Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 3
2012 1
2013 1
2014 1
2015 2
2016 6
2017 7
2018 7
2019 7
2020 15
2021 10
2022 14
2023 19
2024 31
2025 37
2026 19

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

162 results

Results by year

Filters applied: . Clear all
Page 1
Tauroursodeoxycholic acid ameliorates renal injury induced by COL4A3 mutation.
Yu S, Gu X, Zheng Q, Liu Y, Suhas T, Du W, Xie L, Fang Z, Zhao Y, Yang M, Xu J, Wang Y, Lin MH, Pan X, Miner JH, Jin Y, Xie J. Yu S, et al. Among authors: zhao y. Kidney Int. 2024 Sep;106(3):433-449. doi: 10.1016/j.kint.2024.04.015. Epub 2024 May 21. Kidney Int. 2024. PMID: 38782199 Free PMC article.
Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial.
Niu N, Xue J, Chen G, Qiu F, Xu Q, Zheng X, Liu C, Zhao Y, Gu X, Zhao Y, Xu H, Zhang H, He G, Li K, Li P, Chen X, Li Y, Wang S, Zhu D, Liu T, Xing F, Xu Y, Han Y, Tang M, Liu M, Jiao G, Jiang X, Yuen T, Pang Z, Liu C. Niu N, et al. Among authors: zhao y. Nat Commun. 2025 Jul 1;16(1):6036. doi: 10.1038/s41467-025-61213-2. Nat Commun. 2025. PMID: 40593759 Free PMC article. Clinical Trial.
A pilot trial of neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for triple-positive breast cancer.
Huo S, Xue J, Wang S, Shan H, Chen G, Niu N, Wang Y, Qiu F, Zhao Y, Xing F, Zheng X, Tu W, Li K, Zhao H, Tang M, Xu Q, Liu C, Zhao Y, Jiang X, Pang Z, Zhang K, Zhang D, Chen ZS, Liu C. Huo S, et al. Among authors: zhao y. MedComm (2020). 2024 Mar 10;5(3):e505. doi: 10.1002/mco2.505. eCollection 2024 Mar. MedComm (2020). 2024. PMID: 38469548 Free PMC article.
CD73: Friend or Foe in Lung Injury.
Hu XM, Shi NR, Zhang JZ, Zuo YQ, Wang X, Zhao YF, Wu JS. Hu XM, et al. Int J Mol Sci. 2023 Mar 14;24(6):5545. doi: 10.3390/ijms24065545. Int J Mol Sci. 2023. PMID: 36982618 Free PMC article. Review.
Exploration of Gene Therapy for Alport Syndrome.
Zhao Y, Zheng Q, Xie J. Zhao Y, et al. Biomedicines. 2024 May 23;12(6):1159. doi: 10.3390/biomedicines12061159. Biomedicines. 2024. PMID: 38927366 Free PMC article. Review.
Neoadjuvant chidamide combined with chemotherapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (MUKDEN 05): a multicentre, single-arm, phase 2 trial.
Xue J, Shan H, Qiu F, Niu N, Chen G, Xu Q, Gu X, Xing F, Xu Y, Zheng X, He G, Xu H, Zhang H, Song D, Han Y, Tang M, Cao S, Song Y, Zheng R, Zhao Y, Jiao G, Liu M, Liu C. Xue J, et al. Among authors: zhao y. Lancet Reg Health West Pac. 2025 Sep 27;63:101700. doi: 10.1016/j.lanwpc.2025.101700. eCollection 2025 Oct. Lancet Reg Health West Pac. 2025. PMID: 41080407 Free PMC article.
162 results